Clinical trials
Locally Advanced Breast Cancer clinical trials
Below are recruiting locally advanced breast cancer clinical trials, each written for real people, not researchers. We’re tracking 728 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06002789RecruitingPhase 2
PD-1 immunotherapy with or without chemo before surgery for colorectal cancer
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
Guangzhou, GuangdongAges 18–80 - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+ - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Stamford, ConnecticutAges 18 years+ - NCT06111274RecruitingPhase 2
ABSK021 for untreated advanced pancreatic cancer
This trial tests a new drug called ABSK021 for people with advanced pancreatic cancer who have not received any prior treatment. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06151743RecruitingPhase 2
Testing drug combo before throat cancer surgery
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06598761Recruiting
Immunotherapy plus radiation after surgery for advanced UTUC
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
BeijingAges 18–80 - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07357207Enrolling by invitation
Video-immunotherapy for advanced breast cancer
This trial tests if a video-based immunotherapy approach can help treat locally advanced breast cancer. It is designed for people who can communicate in Turkish and are comfortable playing video games as part of their treatment.
Izmir, BalcovaAges 18 years+ - NCT07298200RecruitingPhase 1
XH001 injection plus T-cells for advanced gastric cancer
This trial tests a new treatment combining an injection (XH001) with specially made immune cells (T-cells) that target your tumor's unique markers. It's for people with advanced stomach cancer who have not responded to standard therapies.
Nanjing, JiangsuAges 18–70 - NCT07108309RecruitingPhase 2
Study of BCD-236 with chemotherapy for recurrent triple-negative breast cancer
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
BrestAges 18–74 - NCT06954480RecruitingPhase 2
Two drugs vs one for PDL1-negative breast cancer
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
LondonAges 18 years+ - NCT06762483Recruiting
Blood test for gene changes in advanced breast cancer
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Milan, ItalyAges 18 years+ - NCT06731140RecruitingPhase 2
Reversing immune resistance in HER2-negative breast cancer
This trial tests a new treatment to see if it can reverse resistance to immunotherapy in people with HER2-negative breast cancer. It's for patients whose cancer has gotten worse after immunotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06460298RecruitingPhase 1/Phase 2
ProAgio and gemcitabine for triple-negative breast cancer that has spread
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Atlanta, GeorgiaAges 18 years+ - NCT05683418RecruitingPhase 1
Study of a new drug for PIK3CA-mutated HR+ HER2- breast cancer
This early-stage study tests the safety and tolerability of TOS-358 in women with HR-positive, HER2-negative breast cancer that has a specific gene change (PIK3CA). It may help learn whether this targeted treatment is safe enough to move forward.
Chicago, IllinoisAges 18 years+ - NCT05550415RecruitingPhase 2
Simvastatin with chemotherapy for triple-negative breast cancer
This trial studies whether adding simvastatin (a cholesterol medicine) can slow or change how breast cancer spreads in triple-negative breast cancer. It compares outcomes while you receive planned chemotherapy, and you may or may not be taking simvastatin as part of the study treatment.
Jakarta Pusat, DKI JakartaAges 18 years+ - NCT04159818RecruitingPhase 2
Adding immune treatments to improve checkpoint drug response in TNBC
This Phase 2 trial tests strategies meant to “prime” the immune system so that immune checkpoint medicines may work better in people with triple-negative breast cancer that has spread (or can’t be fully cured). You might be considered if your cancer has measurable areas that can be biopsied and you meet specific health and prior-treatment rules.
AmsterdamAges 18 years+ - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT06993506Recruiting
SKB264 alone or combined for advanced HER2- breast cancer
This study is a real-world treatment trial for people with advanced HER2-negative breast cancer (either triple-negative or HR+/HER2-). It tests a drug called SKB264, given alone or with other therapies, and aims to see how well it works in everyday clinical practice.
Hefei, AnhuiAges 18 years+ - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT06895447RecruitingPhase 2
Robot-assisted stomach cancer surgery after chemo or radiation
This trial tests whether using a robotic arm to remove stomach cancer is safe and effective for patients who have already received chemotherapy or radiation. If you have stage III stomach cancer and are healthy enough for surgery, this approach may offer a more precise operation.
Nanjing, JiangsuAges 18–80 - NCT06826079RecruitingPhase 2
Sorbitol plus chemo and immunotherapy for advanced gastric cancer
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Wuhan, HubeiAges 18–70 - NCT05856383Recruiting
HER2-positive metastatic breast cancer drug combination study
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
Hangzhou, ZhejiangAges 18 years+
Hear when a new Locally Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced breast cancer?
- Yes. Clin2 currently lists 728 recruiting locally advanced breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Locally Advanced or Metastatic Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Advanced Breast Cancer
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced Pancreatic Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.